ReviewInternational journal of molecular sciences2018
Molecular Epidemiology and Evolution of European Bat Lyssavirus 2.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Cat-Related Injuries and Rabies Exposure: A Three-Decade Retrospective Analysis from the Zagreb Antirabies Clinic (1995-2025).Viruses · 2026Article
- Leveraging organoid models to understand mechanisms of viral infections and immunity in bats.Disease models & mechanisms · 2026Review
- Case report: an atypical case of EBLV-1 infection in the long distance migrant bat Pipistrellus nathusii in mainland France.Veterinary research communications · 2026Article
- The Challenge of Lyssavirus Infections in Domestic and Other Animals: A Mix of Virological Confusion, Consternation, Chagrin, and Curiosity.Pathogens (Basel, Switzerland) · 2025Review
- Minimal risk ofFrontiers in microbiology · 2025Article
- Detection and Serological Evidence of European Bat Lyssavirus 1 in Belgian Bats between 2016 and 2018.Tropical medicine and infectious disease · 2024Article
- Tick-borne viruses and their risk to public health in the Caribbean: Spotlight on bats as reservoirs in Cuba.Heliyon · 2024Review
- Investigating the emergence of a zoonotic virus: phylogenetic analysis of European bat lyssavirus 1 in the UK.Virus evolution · 2024Article
- Phylogeographic Aspects of Bat Lyssaviruses in Europe: A Review.Pathogens (Basel, Switzerland) · 2023Review
- Emerging Rhabdoviruses and Human Infection.Biology · 2023Review
- Discovery of a novel bat lyssavirus in a Long-fingered bat (Myotis capaccinii) from Slovenia.PLoS neglected tropical diseases · 2023Article
- Article
- Article
- Novel Bat Lyssaviruses Identified by Nationwide Passive Surveillance in Taiwan, 2018-2021.Viruses · 2022Article
- Article
- Assessing Rabies Vaccine Protection against a Novel Lyssavirus, Kotalahti Bat Lyssavirus.Viruses · 2021Article
- Article
- Genetic and Antigenetic Characterization of the Novel Kotalahti Bat Lyssavirus (KBLV).Viruses · 2021Article
- Article
- Human Tibroviruses: Commensals or Lethal Pathogens?Viruses · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bat rabies cases in Europe are mainly attributed to two lyssaviruses, namely European Bat Lyssavirus 1 (EBLV-1) and European Bat Lyssavirus 2 (EBLV-2). Prior to the death of a bat worker in Finland in 1985, very few bat rabies cases were reported. Enhanced surveillance in the two subsequent years (1986-1987) identified 263 cases (more than a fifth of all reported cases to date). Between 1977 and 2016, 1183 cases of bat rabies were reported, with the vast majority (>97%) being attributed to EBLV-1. In contrast, there have been only 39 suspected cases of EBLV-2, of which 34 have been confirmed by virus typing and presently restricted to just two bat species;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.